SeaStar Medical Holding Corp (ICU) Stock Analysis
Verdict: AVOID
Commercialization of cytopheretic device yields 92.6% gross margin, but $13.6M cash burn creates severe dilution risk by late 2026.
Investment score: 33/100
Analysis as of
Is SeaStar Medical Holding Corp stock worth reviewing? AI model thesis
SeaStar Medical (ICU) faces critical cash burn (-$13.60M FCF) with only $11.98M in cash (~10.5 months runway) and operating margins of -816.64%, posing severe equity dilution risk despite impressive 92.64% gross margins.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
SeaStar Medical Holding Corp opportunities and risks
What speaks for ICU
- High Gross Margin Structure
What speaks against ICU
- Imminent Cash Runway Exhaustion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ICU | n/a | 4.8x | n/a | 92.6% | -795.5% | -167.5% |
| GTHP | n/a | 37.1x | n/a | 64.0% | -573.1% | -6.2% |
| NMTC | n/a | 1.5x | n/a | 55.7% | -71.5% | -49.3% |
| IRIX | n/a | 0.2x | n/a | 36.2% | -6.9% | -14.2% |
| HSCS | n/a | 1505.0x | 195.7x | -2982.1% | -211666.5% | -114.9% |
| ADGM | n/a | 0.0x | n/a | 0.0% | 0.0% | -137.6% |
| Peer median | n/a | 1.5x | n/a | 36.2% | -71.5% | -49.3% |
Frequently asked questions about SeaStar Medical Holding Corp (ICU)
Is ICU stock a good investment?
The cached TradeMates AI model rates SeaStar Medical Holding Corp as AVOID with an investment score of 33/100. SeaStar Medical (ICU) faces critical cash burn (-$13.60M FCF) with only $11.98M in cash (~10.5 months runway) and operating margins of -816.64%, posing severe equity dilution risk despite impressive 92.64% gross margins. This is algorithmic model output, not personal investment advice.
Is ICU stock a buy?
The TradeMates model verdict for ICU is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.